SEKISUI Diagnostics Introduces Rapid COVID-19/Flu A&B Combo Test with 510(k) Approval
In a significant development for respiratory diagnostics, SEKISUI Diagnostics, a distinguished leader in the medical diagnostics domain, has announced the launch of its newly approved OSOM® COVID-19/Flu A&B Combo Test. Set to revolutionize testing in clinical settings, this test offers rapid and reliable results for detecting both COVID-19 and Influenza A and B from a single nasal swab specimen. This innovation comes at a crucial time as healthcare professionals continue to combat the ongoing challenges presented by respiratory infections.
The OSOM® COVID-19/Flu A&B Combo Test has successfully received 510(k) clearance, allowing it to be used in a variety of healthcare settings. The test detects nucleoprotein antigens from influenza A, influenza B, and SARS-CoV-2, which is paramount in ensuring accurate diagnosis during the peak seasons of respiratory illnesses. Given that many patients exhibit overlapping symptoms of COVID-19 and influenza, this multiplex testing approach provides clinicians the tools necessary for timely and accurate diagnostics, helping inform essential clinical decisions rapidly.
One of the standout features of this test is its CLIA waiver, which permits it to be used at the point of care without extensive laboratory settings. This accessibility enhances its practicality in a range of environments, such as urgent care clinics and other healthcare facilities where quick decisions can significantly influence patient outcomes.
Furthermore, the OSOM® COVID-19/Flu A&B Combo Test incorporates a unique characteristic known as QC Inside®, which alleviates the financial burdens associated with separate Quality Control (QC) testing by including it directly within each kit. This feature not only maximizes value for healthcare providers but also allows for two additional patient tests at no extra cost—ensuring that healthcare professionals are aptly equipped for quality assessments right when they are needed.
Erica Blight, the Vice President of Strategy & Growth at SEKISUI Diagnostics, highlighted the importance of this launch amid the recent expiration of Emergency Use Authorizations. Blight remarked, "With the Emergency Use Authorization ending, we know it is extremely important to continue to supply the market with the tools needed to diagnose respiratory infections quickly and accurately. This new product will not only benefit new customers but will also help transition existing customers to a 510(k) cleared alternative, ensuring they remain well-prepared as we transition into the season of respiratory illness."
SEKISUI Diagnostics has been committed to enhancing public health with its innovative diagnostic solutions for over four decades. The company’s robust portfolio of products has established it as a favorable option for point-of-care testing across both professional and home healthcare markets. Its extensive range of medical diagnostics includes clinical chemistry reagents, point-of-care tests, and pre-analytic systems, among others.
In the wake of the ongoing health crisis, the OSOM® COVID-19/Flu A&B Combo Test stands as a testament to SEKISUI Diagnostics’ dedication towards empowering healthcare professionals with the tools necessary to fight infections effectively. Leaders in the industry are optimistic that with heightened diagnosis capabilities, timely intervention can be achieved to alleviate some of the health burdens that are currently being faced worldwide.
As we move forward, the significance of such diagnostic tests cannot be understated, especially as challenges like COVID-19 and seasonal influenza continue to test healthcare systems globally. SEKISUI Diagnostics is poised to play a crucial role in facilitating better health outcomes as medical professionals navigate these complex landscape of respiratory infections.
The OSOM® COVID-19/Flu A&B Combo Test has successfully received 510(k) clearance, allowing it to be used in a variety of healthcare settings. The test detects nucleoprotein antigens from influenza A, influenza B, and SARS-CoV-2, which is paramount in ensuring accurate diagnosis during the peak seasons of respiratory illnesses. Given that many patients exhibit overlapping symptoms of COVID-19 and influenza, this multiplex testing approach provides clinicians the tools necessary for timely and accurate diagnostics, helping inform essential clinical decisions rapidly.
One of the standout features of this test is its CLIA waiver, which permits it to be used at the point of care without extensive laboratory settings. This accessibility enhances its practicality in a range of environments, such as urgent care clinics and other healthcare facilities where quick decisions can significantly influence patient outcomes.
Furthermore, the OSOM® COVID-19/Flu A&B Combo Test incorporates a unique characteristic known as QC Inside®, which alleviates the financial burdens associated with separate Quality Control (QC) testing by including it directly within each kit. This feature not only maximizes value for healthcare providers but also allows for two additional patient tests at no extra cost—ensuring that healthcare professionals are aptly equipped for quality assessments right when they are needed.
Erica Blight, the Vice President of Strategy & Growth at SEKISUI Diagnostics, highlighted the importance of this launch amid the recent expiration of Emergency Use Authorizations. Blight remarked, "With the Emergency Use Authorization ending, we know it is extremely important to continue to supply the market with the tools needed to diagnose respiratory infections quickly and accurately. This new product will not only benefit new customers but will also help transition existing customers to a 510(k) cleared alternative, ensuring they remain well-prepared as we transition into the season of respiratory illness."
SEKISUI Diagnostics has been committed to enhancing public health with its innovative diagnostic solutions for over four decades. The company’s robust portfolio of products has established it as a favorable option for point-of-care testing across both professional and home healthcare markets. Its extensive range of medical diagnostics includes clinical chemistry reagents, point-of-care tests, and pre-analytic systems, among others.
In the wake of the ongoing health crisis, the OSOM® COVID-19/Flu A&B Combo Test stands as a testament to SEKISUI Diagnostics’ dedication towards empowering healthcare professionals with the tools necessary to fight infections effectively. Leaders in the industry are optimistic that with heightened diagnosis capabilities, timely intervention can be achieved to alleviate some of the health burdens that are currently being faced worldwide.
As we move forward, the significance of such diagnostic tests cannot be understated, especially as challenges like COVID-19 and seasonal influenza continue to test healthcare systems globally. SEKISUI Diagnostics is poised to play a crucial role in facilitating better health outcomes as medical professionals navigate these complex landscape of respiratory infections.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.